Results 171 to 180 of about 35,022 (298)

The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients. [PDF]

Cureus, 2023
Chopra VK, Mohanan PP, Kher V, Mantri RR, Isaacs R, Jadhav U, Zalte N, Sugumaran A, Mohanasundaram S.   +8 more
europepmc   +1 more source

Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin‐Induced Nephrotoxicity

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Background Vancomycin (VCM), a first‐line treatment option for infections caused by methicillin‐resistant Staphylococcus aureus, has been reported to cause nephrotoxicity even within therapeutic concentration ranges. Traditional therapeutic drug monitoring strategies rely primarily on the area under the concentration–time curve (AUC), without ...
Yoshihiko Matsuki, Ken‐ichi Sako, Yutaro Kozima, Tamaki Watanabe, Yasuharu Kashiwagura, Nobuhiro Yasuno, Shigekazu Watanabe   +6 more
wiley   +1 more source

An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial

, 2017
Jennifer S. Hanberg, W.H. Wilson Tang, F. Perry Wilson, Steven G. Coca, Tariq Ahmad, Meredith A. Brisco, Jeffrey M. Testani   +6 more
openalex   +2 more sources

Duplicate Prescription Patterns in Patients With Substance Use Disorders

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT This study sought to investigate the frequency and characteristics of duplicate prescriptions (DPs) in psychiatric inpatients with substance use disorders using a DP classification that differentiates between appropriate DPs (ADPs) and potentially inappropriate DPs (PIDPs). The study was conducted as a monocentric retrospective cross‐sectional
Johannes Heck, Benjamin Krichevsky, Martin Schulze Westhoff, Konstantin Fritz Jendretzky, Martin Klietz, Stephan Greten, Alexander Glahn, Stefan Bleich, Sebastian Schröder   +8 more
wiley   +1 more source

Structural changes in the human stria vascularis induced by aminoglycosides and loop diuretics

, 2022
A. Wright, Andrew Forge, Daniel J. Jagger   +2 more
openalex   +1 more source

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 895-905, February 2026.
Abstract Aim A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. Methods Glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
Abigail Postema, Jordy Gaspersz, Brenda N. Baak, Eline L. Huisman, Charlotte Hoogstraten, Lise Meinicke Hagelund, Fernie J. A. Penning‐van Beest, Jetty A. Overbeek   +7 more
wiley   +1 more source

Association between changes in loop diuretic dose and outcomes in acute heart failure. [PDF]

ESC Heart Fail, 2023
Seko Y, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y, Ozasa N, Shiba M, Yamamoto E, Yoshikawa Y, Yamashita Y, Kitai T, Taniguchi R, Iguchi M, Nagao K, Kawai T, Komasa A, Nishikawa R, Kawase Y, Morinaga T, Toyofuku M, Furukawa Y, Ando K, Kadota K, Sato Y, Kuwahara K, Kimura T, KCHF Study Investigators.   +27 more
europepmc   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Relative Blood Volume Profiles Hours After Loop Diuretic Administration: A Systematic Review and Meta-analysis. [PDF]

CJC Open, 2023
Lucas BP, Misra S, Donnelly WT, Daubenspeck JA, Leiter JC.   +4 more
europepmc   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source